<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705337</url>
  </required_header>
  <id_info>
    <org_study_id>2019/ABM/01/00017</org_study_id>
    <nct_id>NCT04705337</nct_id>
  </id_info>
  <brief_title>Levosimendan In Ambulatory Heart Failure Patients</brief_title>
  <acronym>LEIA-HF</acronym>
  <official_title>Levosimendan In Ambulatory Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Opole</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Lodz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nicolaus Copernicus University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cardiology, Warsaw, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>John Paul II Hospital, Krakow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera dei Colli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine the efficacy of repeated infusions of levosimendan&#xD;
      in the group of outpatients with advanced systolic heart failure (HF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a multicentre, randomized, double-blind, placebo-controlled study. 350 subjects will be&#xD;
      included (in 12 or more medical centers) with severe HF, ejection fraction ≤35%, in New York&#xD;
      Heart Association class III or IV. The other inclusion criteria concern: hospitalization for&#xD;
      the HF decompensation in the last 3 months and a reduced six-minute walk test &lt;350m or&#xD;
      elevated NTproBNP ≥1000 pg / mL. To the European Society of Cardiology-guided, individually&#xD;
      optimized medical therapy (OMT) the investigational product (IP) will be added. The subjects&#xD;
      will be randomly assigned to one of the study group: 175 to the levosimendan arm and 175 to&#xD;
      the placebo arm. The intervention studied in LEIA-HF trial is the administration of&#xD;
      levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in&#xD;
      total). All study participants will also continue OMT. In the second phase of the study,&#xD;
      after completing the levosimendan / placebo infusions, another 6 visits are planned, still&#xD;
      double-blind, every 4 weeks, to assess the safety of treatment discontinuation (with optional&#xD;
      return to the infusions by the Investigator when additional criteria for HF decompensation&#xD;
      are met).&#xD;
&#xD;
      The efficacy of the treatment will be assessed after 52 weeks, 4 weeks after the last&#xD;
      levosimendan / placebo administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of unplanned hospitalization</measure>
    <time_frame>12 months of follow-up period</time_frame>
    <description>unplanned hospitalization due to heart failure decompensation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the number of deaths</measure>
    <time_frame>12 months of follow-up period</time_frame>
    <description>death for any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total mortality calculations</measure>
    <time_frame>0-12, 12-18 and 0-18 months</time_frame>
    <description>total mortality for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular mortality calculations</measure>
    <time_frame>0-12, 12-18 and 0-18 months</time_frame>
    <description>mortality due to cardiovascular reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of planned hospitalization</measure>
    <time_frame>0-12, 12-18 and 0-18 months</time_frame>
    <description>planned hospitalization due to heart failure decompensation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of implantations of mechanical circulatory support</measure>
    <time_frame>0-12, 12-18 and 0-18 months</time_frame>
    <description>implantation of mechanical circulatory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of heart transplantations</measure>
    <time_frame>0-12, 12-18 and 0-18 months</time_frame>
    <description>heart transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measurements</measure>
    <time_frame>0-12, 12-18 and 0-18 months</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire quality of life questionnaire- an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the six-minute walk test</measure>
    <time_frame>0-12, 12-18 and 0-18 months</time_frame>
    <description>measures the distance an individual is able to walk over a total of six minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTproBNP measurements</measure>
    <time_frame>0-12, 12-18 and 0-18 months</time_frame>
    <description>measurements of NTproBNP concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate measurements</measure>
    <time_frame>0-12, 12-18 and 0-18 months</time_frame>
    <description>measurements of estimated glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiographic parameters</measure>
    <time_frame>0-12, 12-18 and 0-18 months</time_frame>
    <description>the change in echocardiographic parameters assessed in transthoracic echocardiographic examination (TTE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients who returned to levosimendan / placebo infusions</measure>
    <time_frame>from the 12th to the 18th months of the study</time_frame>
    <description>calculations of the percentage of patients who returned to levosimendan / placebo infusions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Heart Failure New York Heart Association Class III</condition>
  <condition>Heart Failure New York Heart Association Class IV</condition>
  <condition>Heart Failure, Systolic</condition>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of levosimendan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administration of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial activities&#xD;
&#xD;
          -  Male or female, age ≥ 18 years at the time of signing informed consent&#xD;
&#xD;
          -  Left ventricle ejection fraction ≤ 35%&#xD;
&#xD;
          -  Hospitalization due to worsening of HF within the last 3 months&#xD;
&#xD;
          -  New York Heart Association functional class III or outpatient IV&#xD;
&#xD;
          -  Individually optimized pharmacotherapy, based on the current European Society of&#xD;
             Cardiology recommendations, stable for at least 1 month prior to randomization,&#xD;
             according to the knowledge and experience of the qualifying clinician&#xD;
&#xD;
          -  Distance covered in six-minute walk test &lt;350m OR NTproBNP concentration ≥ 1000 pg/mL&#xD;
&#xD;
          -  In the opinion of the Investigator, the patient does not currently require&#xD;
             hospitalization&#xD;
&#xD;
          -  Patient protected with an implantable device capable of terminating life-threatening&#xD;
             arrhythmias and conduction disturbances (ICD or cardiac resynchronisation&#xD;
             therapy-D/P), if indicated and the patient consents to implantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial products or related products,&#xD;
&#xD;
          -  Restrictive or hypertrophic cardiomyopathy, uncorrected severe valvular disease,&#xD;
             potentially reversible cause of HF&#xD;
&#xD;
          -  Hypotension with symptoms of tissue hypoperfusion&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Planned revascularization or other surgical treatment of HF within the next year&#xD;
&#xD;
          -  Advanced chronic kidney disease&#xD;
&#xD;
          -  Features of liver damage&#xD;
&#xD;
          -  Severe chronic lung disease with features of respiratory distress or severe abnormal&#xD;
             spirometry or home oxygen treatment&#xD;
&#xD;
          -  Accompanying chronic diseases with poor prognosis&#xD;
&#xD;
          -  Paroxysmal supraventricular tachycardia, paroxysmal ventricular tachycardia, torsade&#xD;
             de pointes, advanced atrioventricular blocks within one month prior to screening&#xD;
&#xD;
          -  Receipt of any investigational product within 30 days before screening visit&#xD;
&#xD;
          -  Any disorder, which in the investigator's opinion may jeopardise subject's safety or&#xD;
             compliance with the study protocol and procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnieszka Tycińska, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Bialystok</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marek Gierlotka, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Opole</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jarosław Kasprzak, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Łódź</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacek Kubica, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nicolaus Copernicus University in Toruń</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grzegorz Grześk, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nicolaus Copernicus University in Toruń</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jadwiga Nessler, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Paul II Hospital, Krakow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janina Stępińska, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardinal Stefan Wyszyński Institute of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ewa Straburzyńska-Migaj, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poznan University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnieszka Tycińska, Prof.</last_name>
    <phone>+48 85 831 8656</phone>
    <email>agnieszka.tycinska@umb.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrzej Malkowski, PhD</last_name>
    <phone>+48 85 686 5122</phone>
    <email>andrzej.malkowski@umb.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Bialystok Clinical Hospital</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Agnieszka Tycinska, Prof. MD</last_name>
      <email>agnieszka.tycinska@umb.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Agnieszka Tycinska, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Hospital No.1</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacek Kubica, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Jacek Kubica, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Hospital No.2</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Grzegorz Grześk, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Grzegorz Grześk, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Miłosz Jaguszewski, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Miłosz Jaguszewski, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Górnośląskie Centrum Medyczne Śląskiego Uniwersytetu Medycznego</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Wojciech Wojakowski, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Wojciech Wojakowski, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Kraków</city>
        <zip>30-688</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Barbara Zawiślak, PhD MD</last_name>
    </contact>
    <investigator>
      <last_name>Barbara Zawiślak, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Paul II Hospital</name>
      <address>
        <city>Kraków</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Jadwiga Nessler, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Jadwiga Nessler, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Hospital</name>
      <address>
        <city>Opole</city>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Marek Gierlotka, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Marek Gierlotka, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lord's Transfiguration</name>
      <address>
        <city>Poznań</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Ewa Straburzyńska-Migaj, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Ewa Straburzyńska-Migaj, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Renata Główczyńska, ScD PhD MD</last_name>
    </contact>
    <investigator>
      <last_name>Renata Główczyńska, ScD PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Stefan Wyszyński Institute of Cardiology</name>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Janina Stępińska, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Janina Stępińska, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Zymliński, ScD PhD MD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Zymliński, ScD PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Śląskie Centrum Chorób Serca</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Mariusz Gąsior, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Mariusz Gąsior, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Provincial Specialist Hospital named after Dr. Wł. Biegański</name>
      <address>
        <city>Łódź</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Jarosław Kasprzak, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Jarosław Kasprzak, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 10, 2021</last_update_submitted>
  <last_update_submitted_qc>January 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>According to the agreement with the funding institution (Medical Research Agency), the sponsor and research centers must obtain the consent of the funding institution to disclose the clinical trial data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

